Canakinumab for Treatment of Adult-onset Still's Disease

NCT02204293 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

36

Enrollment

OTHER

Sponsor class

Stopped Recruitment issues due to marketing authorization of study drug

Conditions

Adult-Onset Still´s Disease

Interventions

DRUG: Canakinumab
DRUG: Placebo

Sponsor

Charite University, Berlin, Germany